2m 2m 2m 2m 2m 2m 2m
ProQR Therapeut (PRQR)
NASDAQ
$1.42-$0.05 (-3.40%)
Price as of Jun 03, 2026 7:23 PM EDT- $166.2MMarket Cap
- -17.42%1-Year Change
- BiotechnologyIndustry
ProQR Therapeut (PRQR)
$1.42-$0.05 (-3.40%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 15.9M -15.86% | 18.9M +190.22% | 6.5M +61.36% | 4.0M +198.15% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 15.9M -15.86% | 18.9M +190.22% | 6.5M +61.36% | 4.0M +198.15% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -44.7M +23.04% | -36.4M +44.57% | -25.1M -50.56% | -50.9M +20.48% | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Operating Expenses | 15.1M +10.24% | 13.7M -15.86% | 16.2M -12.95% | 18.7M +7.39% | |
Operating Profit | -43.4M +42.58% | -30.5M -4.35% | -31.9M -50.77% | -64.7M +13.16% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -929,000 -13.74% | -1.1M -10.47% | -1.2M -41.03% | -2.0M -40.09% | |
Interest Income and Expense and Net | -929,000 -13.74% | -1.1M -10.47% | -1.2M -41.03% | -2.0M -40.09% | |
Total Nonoperating Income and Expense | 441,000 -31.09% | 640,000 -78.74% | 3.0M +293.59% | 765,000 -26.65% | |
Income before Taxes | -42.2M +51.94% | -27.8M +0.10% | -27.7M -57.26% | -64.9M +5.21% | |
Income Taxes | 19,000 +109.64% | -197,000 +152.56% | -78,000 -181.25% | 96,000 -17.95% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -42.2M +51.94% | -27.8M +0.10% | -27.7M -57.26% | -64.9M +5.21% | |
Net Income from Continuing Operations Applicable to Common | -42.2M +51.94% | -27.8M +0.10% | -27.7M -57.26% | -64.9M +5.21% | |
Basic EPS and Net Income | -0.40 +25.00% | -0.32 -8.57% | -0.35 -61.54% | -0.91 -5.21% | |
Diluted EPS and Net Income | -0.40 +25.00% | -0.32 -8.57% | -0.35 -61.54% | -0.91 -5.21% | |
Basic Weighted Average Shares | 105.3M +22.36% | 86.1M +6.26% | 81.0M +13.08% | 71.6M +11.62% | |
Diluted Weighted Average Shares | 105.3M +22.36% | 86.1M +6.26% | 81.0M +13.08% | 71.6M +11.62% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 92.4M -38.15% | 149.4M +25.63% | 118.9M +25.48% | 94.8M -49.46% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 92.4M -38.15% | 149.4M +25.63% | 118.9M +25.48% | 94.8M -49.46% | |
Total Current Assets | 100.1M -34.92% | 153.8M +27.16% | 121.0M -21.67% | 154.5M -19.33% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | N/A N/A | 16.2M -7.02% | |
Total Long-Term Assets | 12.6M -10.51% | 14.1M -16.48% | 16.9M +0.21% | 16.9M -6.82% | |
Total Assets | 112.8M -32.87% | 168.0M +21.81% | 137.9M -19.52% | 171.3M -18.25% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 32.4M -16.61% | 38.9M +13.74% | 34.2M +62.01% | 21.1M -23.50% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 30.9M -23.59% | 40.5M -34.99% | 62.3M -26.80% | 85.1M +23.77% | |
Total Liabilities | 63.4M -20.17% | 79.4M -17.72% | 96.5M -9.15% | 106.2M +10.23% | |
Retained Earnings | -467.5M +9.45% | -427.2M +6.56% | -400.9M +5.30% | -380.7M +19.80% | |
Total Stockholders Equity | 49.4M -44.25% | 88.6M +113.96% | 41.4M -36.43% | 65.1M -42.49% | |
Total Shares Outstanding | 725,692 -99.33% | 107.7M +27.85% | 84.2M +0.002% | 84.2M +11,509.19% | |
Cash Flow | |||||
Cash from Operating Activities | -52.8M +45.06% | -36.4M -268.89% | 21.5M +131.45% | -68.5M +163.37% | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | -1.0M -74.96% | -4.1M -195.21% | 4.3M +709.40% | -702,000 +65.18% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -1.8M -102.61% | 70.3M +3,189.05% | -2.3M -92.64% | -30.9M -122.58% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -273.14% +69.46% | -161.18% -67.04% | -489.08% -69.49% | -1,603.07% -62.05% | |
Return on Assets | -30.05% +65.54% | -18.16% +1.20% | -17.94% -47.35% | -34.07% -14.84% | |
Return on Equity | -61.17% +43.15% | -42.73% -17.96% | -52.08% -28.43% | -72.77% +0.15% | |
Revenue Growth | -15.86% -108.34% | 190.22% +210.02% | 61.36% -69.04% | 198.15% N/A | |
Current Ratio | 3.09 -21.96% | 3.95 +11.80% | 3.54 -51.65% | 7.32 +5.44% | |
Cash Ratio | 2.85 -25.83% | 3.84 +10.46% | 3.48 -22.55% | 4.49 -33.94% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow